Hagn, G.
, Meier-Menches, S. M., Plessl-Walder, G., Mitra, G.
, Mohr, T., Preindl, K., Schlatter, A., Schmidl, D.
, Gerner, C., Garhöfer, G.
, & Bileck, A. (2024).
Plasma Instead of Serum Avoids Critical Confounding of Clinical Metabolomics Studies by Platelets.
Journal of Proteome Research.
https://doi.org/10.1021/acs.jproteome.3c00761
Ries, A., Flehberger, D.
, Slany, A., Pirker, C.
, Mader, J. C., Mohr, T., Schelch, K., Sinn, K., Mosleh, B., Hoda, M. A., Dome, B., Dolznig, H., Krupitza, G., Müllauer, L.
, Gerner, C., Berger, W., & Grusch, M. (2023).
Mesothelioma-associated fibroblasts enhance proliferation and migration of pleural mesothelioma cells via c-Met/PI3K and WNT signaling but do not protect against cisplatin.
Journal of Experimental and Clinical Cancer Research,
42(1), [27].
https://doi.org/10.1186/s13046-022-02582-0
Baier, D.
, Mendrina, T., Schoenhacker-Alte, B., Pirker, C.
, Mohr, T., Rusz, M., Regner, B.
, Schaier, M., Sgarioto, N., Raynal, N. J. M., Nowikovsky, K., Schmidt, W. M., Heffeter, P.
, Meier-Menches, S. M., Koellensperger, G., Keppler, B. K., & Berger, W. (2023).
The Lipid Metabolism as Target and Modulator of BOLD-100 Anticancer Activity: Crosstalk with Histone Acetylation.
Advanced science,
10(32), [2301939].
https://doi.org/10.1002/advs.202301939
Mödl, B., Awad, M., Zwolanek, D., Scharf, I., Schwertner, K., Milovanovic, D., Moser, D.
, Schmidt, K., Pjevac, P., Hausmann, B., Krauß, D.
, Mohr, T., Svinka, J., Kenner, L., Casanova, E., Timelthaler, G., Sibilia, M., Krieger, S., & Eferl, R. (2023).
Defects in microvillus crosslinking sensitize to colitis and inflammatory bowel disease.
EMBO Reports,
24(10), [e57084].
https://doi.org/10.15252/embr.202357084
Janker, L., Schuster, D.
, Bortel, P., Hagn, G.
, Meier-Menches, S. M., Mohr, T., Mader, J. C., Slany, A., Bileck, A., Brunmair, J., Madl, C., Unger, L., Hennlich, B., Weitmayr, B.
, Del Favero, G., Pils, D., Pukrop, T., Pfisterer, N., Feichtenschlager, T.
, & Gerner, C. (2023).
Multi-omics empowered deep phenotyping of ulcerative colitis identifies biomarker signatures reporting functional remission states.
Journal of Crohn's & colitis,
17(9), 1514-1527.
https://doi.org/10.1093/ecco-jcc/jjad052
Ries, A.
, Slany, A., Pirker, C.
, Mader, J. C., Mejri, D.
, Mohr, T., Schelch, K., Flehberger, D., Maach, N., Hashim, M., Hoda, M. A., Dome, B., Krupitza, G., Berger, W.
, Gerner, C., Holzmann, K., & Grusch, M. (2023).
Primary and hTERT-Transduced Mesothelioma-Associated Fibroblasts but Not Primary or hTERT-Transduced Mesothelial Cells Stimulate Growth of Human Mesothelioma Cells.
Cells,
12(15), [2006].
https://doi.org/10.3390/cells12152006
Caban, M., Koblmueller, B., Groza, D., Schueffl, H. H., Terenzi, A., Tolios, A.
, Mohr, T., Mathuber, M., Kryeziu, K., Jaunecker, C., Pirker, C.
, Keppler, B. K., Berger, W.
, Kowol, C. R., & Heffeter, P. (2023).
A novel EGFR inhibitor acts as potent tool for hypoxia-activated prodrug systems and exerts strong synergistic activity with VEGFR inhibition in vitro and in vivo.
Cancer Letters,
565, [216237].
https://doi.org/10.1016/j.canlet.2023.216237
Ertl, I. E., Brettner, R., Kronabitter, H.
, Mohr, T., Derdak, S., Jeitler, M., Bilban, M., Garstka, N., & Shariat, S. F. (2023).
The SMARCD Family of SWI/SNF Accessory Proteins Is Involved in the Transcriptional Regulation of Androgen Receptor-Driven Genes and Plays a Role in Various Essential Processes of Prostate Cancer.
Cells,
12(1), [124].
https://doi.org/10.3390/cells12010124
Malik, B., Vokic, I.
, Mohr, T., Poppelaars, M., Holcmann, M., Novoszel, P., Timelthaler, G., Lendl, T., Krauss, D., Elling, U., Mildner, M., Penninger, J. M., Petzelbauer, P., Sibilia, M., & Csiszar, A. (2023).
FAM3C/ILEI protein is elevated in psoriatic lesions and triggers psoriasiform hyperproliferation in mice.
EMBO Molecular Medicine,
15(7), [e16758].
https://doi.org/10.15252/emmm.202216758
Moritsch, S., Moedl, B., Scharf, I., Janker, L., Zwolanek, D., Timelthaler, G., Casanova, E., Sibilia, M.
, Mohr, T., Kenner, L., Herndler-Brandstetter, D.
, Gerner, C., Mueller, M., Strobl, B., & Eferl, R. (2022).
Tyk2 is a tumor suppressor in colorectal cancer.
OncoImmunology,
11(1), [2127271].
https://doi.org/10.1080/2162402X.2022.2127271